J.P. Morgan Private Wealth Advisors LLC - FATE THERAPEUTICS INC ownership

FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.

Quarter-by-quarter ownership
J.P. Morgan Private Wealth Advisors LLC ownership history of FATE THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$280,548
-56.4%
132,334
-2.2%
0.00%
-66.7%
Q2 2023$644,190
-17.7%
135,334
-1.5%
0.00%
+50.0%
Q1 2023$783,129
+389.1%
137,391
+765.7%
0.00%
Q4 2022$160,128
-55.0%
15,870
-0.1%
0.00%
-100.0%
Q3 2022$356,000
-10.6%
15,880
-1.2%
0.00%0.0%
Q2 2022$398,000
-38.2%
16,073
-3.2%
0.00%0.0%
Q1 2022$644,000
-40.7%
16,603
-10.6%
0.00%
-50.0%
Q4 2021$1,086,000
+0.3%
18,565
+1.6%
0.00%
-33.3%
Q3 2021$1,083,000
-36.1%
18,274
-6.5%
0.00%
-25.0%
Q2 2021$1,695,000
+3.6%
19,534
-1.6%
0.00%
-20.0%
Q1 2021$1,636,000
-11.7%
19,846
-2.6%
0.01%
-16.7%
Q4 2020$1,853,000
+144.1%
20,380
+7.4%
0.01%
+100.0%
Q3 2020$759,000
+120.6%
18,979
+89.6%
0.00%
+50.0%
Q2 2020$344,000
-0.6%
10,012
-35.8%
0.00%0.0%
Q1 2020$346,000
+13.4%
15,5920.0%0.00%
+100.0%
Q4 2019$305,000
+48.8%
15,592
+17.8%
0.00%0.0%
Q3 2019$205,000
-73.2%
13,232
-64.8%
0.00%
-75.0%
Q2 2019$764,000
+15.6%
37,6320.0%0.00%
+33.3%
Q1 2019$661,000
+36.9%
37,6320.0%0.00%0.0%
Q4 2018$483,00037,6320.00%
Other shareholders
FATE THERAPEUTICS INC shareholders Q3 2023
NameSharesValueWeighting ↓
Polaris Venture Management Co. V, L.L.C. 569,889$46,987,00060.92%
Johnson & Johnson Innovation - JJDC, Inc. 3,379,064$278,604,00036.08%
Darwin Global Management, Ltd. 1,370,133$112,967,00022.12%
Redmile Group, LLC 12,957,222$1,068,323,00015.05%
Copernicus Capital Management, LLC 8,000$660,00010.66%
Casdin Capital, LLC 3,400,000$280,330,0008.35%
Grosvenor Holdings, L.L.C. 1,123,576$92,639,0006.81%
DAFNA Capital Management LLC 314,360$25,919,0006.15%
Ally Bridge Group (NY) LLC 270,000$22,262,0004.27%
Ghost Tree Capital, LLC 185,000$15,253,0003.58%
View complete list of FATE THERAPEUTICS INC shareholders